LT2699545T - Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui - Google Patents

Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui

Info

Publication number
LT2699545T
LT2699545T LTEP12722423.6T LT12722423T LT2699545T LT 2699545 T LT2699545 T LT 2699545T LT 12722423 T LT12722423 T LT 12722423T LT 2699545 T LT2699545 T LT 2699545T
Authority
LT
Lithuania
Prior art keywords
prevention
treatment
metabolic syndrome
novel amino
pyrroline derivatives
Prior art date
Application number
LTEP12722423.6T
Other languages
English (en)
Inventor
Pascal Bousquet
Jean Daniel EHRHARDT
Lyne FELLMANN
Vincent GASPARIK
Hugues GRENEY
Mohamed HADJERI
André Mann
Nathalie NIEDERHOFFER
Stephan Schann
Original Assignee
Université De Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1153375A external-priority patent/FR2974364B1/fr
Application filed by Université De Strasbourg filed Critical Université De Strasbourg
Publication of LT2699545T publication Critical patent/LT2699545T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP12722423.6T 2011-04-19 2012-04-17 Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui LT2699545T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1153375A FR2974364B1 (fr) 2011-04-19 2011-04-19 Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique
FR1251302 2012-02-13
PCT/FR2012/050835 WO2012143660A1 (fr) 2011-04-19 2012-04-17 Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique

Publications (1)

Publication Number Publication Date
LT2699545T true LT2699545T (lt) 2016-09-26

Family

ID=46146922

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12722423.6T LT2699545T (lt) 2011-04-19 2012-04-17 Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui

Country Status (17)

Country Link
US (1) US9303019B2 (lt)
EP (1) EP2699545B1 (lt)
JP (1) JP5986625B2 (lt)
CN (1) CN103619814B (lt)
CA (1) CA2833339C (lt)
CY (1) CY1118117T1 (lt)
DK (1) DK2699545T3 (lt)
ES (1) ES2588059T3 (lt)
HR (1) HRP20161024T1 (lt)
HU (1) HUE030432T2 (lt)
LT (1) LT2699545T (lt)
PL (1) PL2699545T3 (lt)
PT (1) PT2699545T (lt)
RS (1) RS55061B1 (lt)
SI (1) SI2699545T1 (lt)
SM (1) SMT201600284B (lt)
WO (1) WO2012143660A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015014191B1 (pt) * 2012-12-19 2019-08-27 Bayer Cropscience Ag indanil carboxamidas difluorometilnicotínicas
WO2023084054A1 (en) 2021-11-12 2023-05-19 3Z Ehf Treatment of adhd using selective binders of the 11-imidazoline receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670859A1 (de) * 1967-04-24 1971-03-11 Bayer Ag Verfahren zur Herstellung von 2-Phenyl-imino-1-azacycloalkanen
US3679692A (en) * 1969-10-01 1972-07-25 Mead Johnson & Co Iminomethylindolines
US4533739A (en) * 1982-10-12 1985-08-06 G. D. Searle & Co. 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
US4579951A (en) * 1984-03-19 1986-04-01 G. D. Searle & Co. Substituted (azacycloalk-2-yl)iminophenols and esters thereof
ES2756499T3 (es) * 2009-10-06 2020-04-27 Allergan Inc Derivados de 2H-pirrol-5-amina como moduladores de receptor alfa adrenérgico
RU2012119247A (ru) * 2009-10-21 2013-11-27 Аллерган, Инк. Модуляторы альфа-адренергических рецепторов

Also Published As

Publication number Publication date
SI2699545T1 (sl) 2016-12-30
CA2833339A1 (fr) 2012-10-26
CN103619814A (zh) 2014-03-05
CN103619814B (zh) 2016-01-20
US9303019B2 (en) 2016-04-05
WO2012143660A1 (fr) 2012-10-26
PL2699545T3 (pl) 2017-01-31
EP2699545B1 (fr) 2016-05-25
CA2833339C (fr) 2020-09-15
RS55061B1 (sr) 2016-12-30
HRP20161024T1 (hr) 2016-11-04
CY1118117T1 (el) 2017-06-28
DK2699545T3 (en) 2016-08-29
EP2699545A1 (fr) 2014-02-26
PT2699545T (pt) 2016-08-30
ES2588059T3 (es) 2016-10-28
JP2014514316A (ja) 2014-06-19
HUE030432T2 (en) 2017-05-29
JP5986625B2 (ja) 2016-09-06
SMT201600284B (it) 2016-11-10
US20140045910A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
GB2478595B (en) Phytocannabinoids in the treatment of glioma
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
PL2739615T3 (pl) Fenylo-3-aza-bicyklo[3.1.0]heks-3-ylo-metanony i ich zastosowanie jako leki
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
SI2854910T1 (sl) Nivoji ceramida pri zdravljenju in preprečevanju okužb
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
ZA201403592B (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB201208850D0 (en) Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
SI2699545T1 (sl) Novi amino-pirolinski derivati in uporaba le-teh pri preprečevanju in/ali zdravljenju metaboličnega sindroma
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
SI2702033T1 (sl) Uporaba soli 3-karboksi-n-etil-n,n-dimteilpropan-1-amina pri zdravljenju bolezni srca in ožilja
PL2771016T3 (pl) Prymycyna i jej składniki do zastosowania w leczeniu lub zapobieganiu infekcjom powodowanym przez określone patogeny
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
AU2012905072A0 (en) The use of bucillamine in the treatment of gout